Please login to the form below

Not currently logged in
Email:
Password:

Two MDs leave CCC

Carsten Edwards, MD of Brandtectonics Access, and Vicky Hunt, MD of Allidura, are leaving Chandler Chicco Companies

Carsten Edwards, MD of Brandtectonics Access, and Vicky Hunt, MD of Allidura, are leaving Chandler Chicco Companies (CCC).

It is believed that Edwards will be moving to Ogilvy Healthworld at the end his three-month notice period. He joined CCC in 2008, first as director at Brandtectonics, and he was promoted to MD in April 2010. Prior to this, Edwards was at Bristol-Myers Squibb.

Vicky Hunt is leaving CCC after 10 years to move out of London and spend more time with her family. While at CCC she worked in three of its business units, leading two of them for periods.

Fiona Hall, EU MD at CCC said: "We are very sad to see Vicky leave but wish her the very best and hope she really enjoys spending more time with her children. We also thank Carsten and wish him well for the future."

A new MD for Allidura will be "announced in due course." It is unclear whether Edwards would be replaced.

Brandtectonics Access underwent a restructure in December 2010 when it was split across a number of CCC businesses following an annual review.

Hall said: "We review our business on an annual basis to consider how we can evolve to best service the needs of our clients moving forward. It became clear to us that our clients' growing market access needs would be best served by integrating our offer across the CCC business units so that market access counsel would be readily available and integrated."

CCC has said it will be looking at how to move Brandtectonics forward in light of these recent changes.

12th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics